SCHEMBL19633722

SCHEMBL19633722

CN(C)c1noc2cnccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 4/20 0.42
LATS2 Q9NRM7 3/20 0.42
EPHX2 P34913 2/20 0.40
CHRM5 P08912 1/20 0.34
CHKA P35790 1/20 0.34
DYRK1A Q13627 2/20 0.34
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
TSHR P16473 1/20 0.33
TDO2 P48775 4/20 0.32
CHUK O15111 1/20 0.32
IDO1 P14902 3/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20439174 0.75 HIF1A (0.44) EPHX2CYP1A2CYP3A4CYP2D6CLK4
SCHEMBL8286072 0.75 EPHX2 (0.43) EPHX2CYP1A2TDO2IDO1MAPK1
SCHEMBL4987598 0.71 EPHX2 (0.43) EPHX2TDO2IDO1HIF1AMTNR1A
SCHEMBL2392643 0.71 EPHX2 (0.43) EPHX2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL11914627 0.70 EPHX2 (0.40) EPHX2DYRK1AALDH1A1TDO2IDO1
SCHEMBL21299799 0.70 EPHX2 (0.40) LATS1LATS2EPHX2CYP3A4ALDH1A1
SCHEMBL15935234 0.70 EPHX2 (0.43) LATS1EPHX2ALDH1A1TSHRTDO2
SCHEMBL18878978 0.70 EPHX2 (0.54) LATS1LATS2EPHX2CYP1A2CYP3A4
SCHEMBL20909684 0.70 CHRNA7 (0.39) CYP1A2CLK4KMT2AALDH1A1TSHR
Bromide SCHEMBL30493633 0.69 EPHX2 (0.42) EPHX2TDO2IDO1MAPK1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10307413-B2 Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2019-06-04 US disclosed
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10307413-B2 Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT3 LATS1 721/4885LATS2 1011/4885EPHX2 2854/4885
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 LATS1 721/4885LATS2 1011/4885EPHX2 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.